Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer

International Journal of Infectious Diseases

Volumn 17, Issue 4, 2013, Pages

  Sudenga, S L ^a   Shrestha, S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cervical cancer; HPV infection; HPV persistence; Intermediate phenotype; Precancerous lesions

Indexed keywords

DISEASE COURSE; DISEASE DURATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; PAPILLOMAVIRUS INFECTION; PERSISTENT VIRUS INFECTION; PHENOTYPE; PRECANCER; REMISSION; SHORT SURVEY; UTERINE CERVIX CANCER; VIRAL CLEARANCE; VIRUS PATHOGENESIS;

FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHENOTYPE; PRECANCEROUS CONDITIONS; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84875366604     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.12.027     Document Type: Short Survey

References (38)

1. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006, 3:e138.
2. Genital HPV infection-fact sheet 2012, Centers for Disease Control and Prevention, CDC, Atlanta, GA.
3. WHO/ICO Information Centre on HPV and Cervical Cancers in World. Summary Report 2010, Barcelona, Spain. Available at: http://www.who.int/hpvcentre.
4. Howlader N., Noone A.M., Krapcho M., Neyman N., Aminou R., Altekruse S.F., et al. SEER cancer statistics review, 1975-2009 (vintage 2009 populations) 2010, National Cancer Institute, Bethesda, MD.
5. Ho G.Y., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338:423-428.
6. Moscicki A.B., Shiboski S., Broering J., Powell K., Clayton L., Jay N., et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998, 132:277-284.
7. Schiffman M., Wentzensen N., Wacholder S., Kinney W., Gage J.C., Castle P.E. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011, 103:368-383.
8. Koshiol J., Lindsay L., Pimenta J.M., Poole C., Jenkins D., Smith J.S. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008, 168:123-137.
9. Syrjanen K. Persistent high-risk human papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation (non-HPV 16/18) prophylactic HPV vaccines. Eur J Gynaecol Oncol 2011, 32:17-33.
10. Chen H.C., Schiffman M., Lin C.Y., Pan M.H., You S.L., Chuang L.C., et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011, 103:1387-1396.
11. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
12. Schiffman M.H., Castle P. Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 2003, 95:E2.
13. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
14. Parkin D.M., Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24(Suppl 3):S11-S25.
15. Rositch A.F., Poole C., Hudgens M.G., Agot K., Nyagaya E., Moses S., et al. Multiple human papillomavirus infections and type competition in men. J Infect Dis 2012, 205:72-81.
16. Thomas K.K., Hughes J.P., Kuypers J.M., Kiviat N.B., Lee S.K., Adam D.E., et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000, 182:1097-1102.
17. Chaturvedi A.K., Myers L., Hammons A.F., Clark R.A., Dunlap K., Kissinger P.J., et al. Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections. Cancer Epidemiol Biomarkers Prev 2005, 14:2439-2445.
18. Kotloff K.L., Wasserman S.S., Russ K., Shapiro S., Daniel R., Brown W., et al. Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis 1998, 25:243-250.
19. Schiffman M., Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med 2003, 127:946-949.
20. Ostor A.G. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993, 12:186-192.
21. Castle P.E., Rodriguez A.C., Burk R.D., Herrero R., Wacholder S., Hildesheim A., et al. Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer. J Infect Dis 2011, 203:814-822. Proyecto Epidemiologico Guanacaste Group.
22. Plummer M., Herrero R., Franceschi S., Meijer C.J., Snijders P., Bosch F.X., et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 2003, 14:805-814.
23. Schmeink C.E., Melchers W.J., Siebers A.G., Quint W.G., Massuger L.F., Bekkers R.L. Human papillomavirus persistence in young unscreened women, a prospective cohort study. PLoS One 2011, 6:e27937.
24. Maucort-Boulch D., Plummer M., Castle P.E., Demuth F., Safaeian M., Wheeler C.M., et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer 2010, 126:684-691.
25. Hildesheim A., Wang S.S. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002, 89:229-240.
26. Castle P.E., Glass A.G., Rush B.B., Scott D.R., Wentzensen N., Gage J.C., et al. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol 2012, 30:3044-3050.
27. Shrestha S., Wang C., Aissani B., Wilson C.M., Tang J., Kaslow R.A. Interleukin-10 gene (IL10) polymorphisms and human papillomavirus clearance among immunosuppressed adolescents. Cancer Epidemiol Biomarkers Prev 2007, 16:1626-1632.
28. Cox T., Cuzick J. HPV DNA testing in cervical cancer screening: from evidence to policies. Gynecol Oncol 2006, 103:8-11.
29. Kjaer S.K., Frederiksen K., Munk C., Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010, 102:1478-1488.
30. Woodman C.B., Collins S.I., Young L.S. The natural history of cervical HPV infection: unresolved issues. Nature Rev Cancer 2007, 7:11-22.
31. Rositch A.F., Koshiol J., Hudgens M., Razzaghi H., Backes D.M., Pimenta J.M., et al. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer 2012, epub ahead of print. 10.1002/ijc.27828.
32. Shrestha S., Sudenga S., Smith J.S., Bachmann L.H., Wilson C.M., Kempf M.C. The Impact of Highly Active Antiretroviral Therapy on Prevalence and Incidence of Cervical Human Papillomavirus Infections in HIV-Positive Adolescents. BMC Infect Dis 2010, 10(1):295.
33. Xue X., Gange S.J., Zhong Y., Burk R.D., Minkoff H., Massad L.S., et al. Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev 2010, 19:159-169.
34. Kong X., Archer K.J., Moulton L.H., Gray R.H., Wang M.C. Parametric frailty models for clustered data with arbitrary censoring: application to effect of male circumcision on HPV clearance. BMC Med Res Methodol 2010, 10:40.
35. Kravchenko J., Akushevich I., Sudenga S.L., Wilson C.M., Levitan E.B., Shrestha S. Transitional probability-based model for HPV clearance in HIV-1-positive adolescent females. PLoS One 2012, 7:e30736.
36. Kong X., Gray R.H., Moulton L.H., Wawer M., Wang M.C. A modeling framework for the analysis of HPV incidence and persistence: a semi-parametric approach for clustered binary longitudinal data analysis. Stat Med 2010, 29:2880-2889.
37. Mitchell C.E., Hudgens M.G., King C.C., Cu-Uvin S., Lo Y., Rompalo A., et al. Discrete-time semi-Markov modeling of human papillomavirus persistence. Stat Med 2011, 30:2160-2170.
38. Sudenga S.L., Royse K.E., Shrestha S. Role and uptake of human papillomavirus vaccine in adolescent health in the United States. Adolesc Health Med and Therap 2011, 2:63-74.